Saw palmetto for the treatment of men with lower urinary tract symptoms

被引:46
作者
Gerber, GS [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Dept Surg, Urol Sect, Chicago, IL 60637 USA
关键词
prostatic hyperplasia; medicine; herbal; urologic diseases; prostate;
D O I
10.1016/S0022-5347(05)67631-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: A comprehensive review of the literature on the use of saw palmetto in men with lower urinary tract symptoms is provided. Materials and Methods: A literature search of studies that have assessed the mechanism of action and clinical results of saw palmetto in men with benign prostatic hyperplasia was performed. Results: A variety of potential mechanisms of action of saw palmetto have been demonstrated through in vitro studies, including 5-alpha reductase inhibition, adrenergic receptor antagonism and intraprostatic androgen receptor blockade. Clinical evidence of the relevance of these effects is largely unavailable. The use of saw palmetto in men with benign prostatic hyperplasia is safe with no recognized adverse effects. No effect on serum prostate specific antigen has been noted. Placebo controlled trials and, meta-analyses have suggested that saw palmetto leads to subjective and objective improvement in men with lower urinary tract symptoms. However, most studies are significantly limited by methodological flaws, small patient numbers and brief treatment intervals. Conclusions: Evidence suggests that saw palmetto may have a significant effect on urinary Row rates and symptom scores compared to placebo in men with lower urinary tract symptoms, However, large scale, placebo controlled trials are needed to assess the efficacy of saw palmetto.
引用
收藏
页码:1408 / 1412
页数:5
相关论文
共 78 条
[61]  
ROEHRBORN CG, 1998, P 4 INT CONS BEN PRO, P437
[62]   STEROID 5-ALPHA-REDUCTASE - 2 GENES 2 ENZYMES [J].
RUSSELL, DW ;
WILSON, JD .
ANNUAL REVIEW OF BIOCHEMISTRY, 1994, 63 :25-61
[63]  
SEMINO MA, 1992, ARCH ESP UROL, V45, P211
[65]   THE VALUE OF PERMIXON IN BENIGN PROSTATIC HYPERTROPHY [J].
SMITH, HR ;
MEMON, A ;
SMART, CJ ;
DEWBURY, K .
BRITISH JOURNAL OF UROLOGY, 1986, 58 (01) :36-40
[66]   Combined Sabal and Urtica extract vs Finasteride in BPH (Alken stage I-II) - Comparison of therapeutic efficacy in a one-year double-blind study [J].
Sokeland, J ;
Albrecht, J .
UROLOGE-AUSGABE A, 1997, 36 (04) :327-333
[67]   Selectivity of finasteride as an in vivo inhibitor of 5α-reductase isozyme enzymatic activity in the human prostate [J].
Span, PN ;
Völler, MCW ;
Smals, AGH ;
Sweep, FGJ ;
Schalken, JA ;
Feneley, MR ;
Kirby, RS .
JOURNAL OF UROLOGY, 1999, 161 (01) :332-337
[68]   Kinetic analysis of steroid 5 alpha-reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostate [J].
Span, PN ;
Benraad, TJ ;
Sweep, CGJ ;
Smals, AGH .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 57 (1-2) :103-108
[69]  
STRAUCH G, 1994, EUR UROL, V26, P247
[70]   INHIBITION OF ANDROGEN METABOLISM AND BINDING BY A LIPOSTEROLIC EXTRACT OF SERENOA REPENS B IN HUMAN FORESKIN FIBROBLASTS [J].
SULTAN, C ;
TERRAZA, A ;
DEVILLIER, C ;
CARILLA, E ;
BRILEY, M ;
LOIRE, C ;
DESCOMPS, B .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1984, 20 (01) :515-519